Implication for health policy/practice/research/medical education:
Metformin, with the chemical name of 1,1-dimethylbiguanide hydrochloride, is in the first line of treatment of patients with type
2 diabetes. Metformin treatment reduced inflammatory markers such as IL-1β, iNOS, and TNF-α, and reduced the number of
microglia cells, and accordingly, it inhibited the inflammatory response. It was indicated that metformin reduced levels of ROS
and NO and increased the antioxidant system, such as SOD.
Please cite this paper as: Hasanpour Dehkordi A, Abbaszadeh A, Mir S, Hasanvand A. Metformin and its anti-inflammatory
and anti-oxidative effects; new concepts. J Renal Inj Prev. 2019;8(1):54-61. DOI: 10.15171/jrip.2019.11.